预约演示
更新于：2026-01-26
Acetaminophen/Oxycodone Hydrochloride
氨酚羟考酮
更新于：2026-01-26
概要
基本信息
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2004-01-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H22ClNO4 |
InChIKeyMUZQPDBAOYKNLO-RKXJKUSZSA-N |
CAS号124-90-3 |
查看全部结构式(2)
关联
40
项与 氨酚羟考酮 相关的临床试验NCT07017452
Methoxyflurane + Lorazepam + Percocet (Per os) vs Deep Intravenous Sedation: A Non-inferiority Randomized Controlled Trial to Assess the Efficacy and Safety During Convective Radiofrequency Water Vapor Thermal Therapy (REZUM) for Benign Prostate Hyperplasia
CTR20250869
氨酚羟考酮缓释片用于治疗术后中重度疼痛的有效性和安全性的多中心、随机、双盲、阳性药和安慰剂对照临床试验
CTR20242166
比较氨酚羟考酮缓释片与氨酚羟考酮片的药代动力学特征并评估食物对氨酚羟考酮缓释片药代动力学的影响研究
100 项与 氨酚羟考酮 相关的临床结果
登录后查看更多信息
100 项与 氨酚羟考酮 相关的转化医学
登录后查看更多信息
100 项与 氨酚羟考酮 相关的专利（医药）
登录后查看更多信息
64
项与 氨酚羟考酮 相关的文献（医药）2025-09-01AMERICAN SURGEON
Outcomes After Implementation of an Enhanced Recovery Protocol for Minimally Invasive Repair of Pectus Excavatum
Article
作者: Spector, Chelsea ; Ngo, Lisa ; Laituri, Carrie ; Levene, Tamar ; Katz, Danielle ; Samuels, Shenae ; Motta, Monique
Background:
Surgical repair of pectus excavatum is commonly associated with significant post-operative pain requiring prolonged hospital stays and critical care admission for sedative and analgesic infusions. By implementing an enhanced recovery after surgery (ERAS) protocol for patients undergoing minimally invasive pectus repair, we aimed to reduce length of hospital stay, need for higher level monitored care, and opioid utilization.
Methods:
A retrospective chart review was performed for all patients under the age of 25 years who underwent Nuss bar insertion at our institution between January 2011 and May 2021. The primary outcomes were hospital length of stay, intensive care unit (ICU) utilization, and opioid consumption before and after the implementation of the ERAS protocol in December 2017.
Results:
A total of 86 patients underwent Nuss repair of pectus excavatum, including 14 patients in the ERAS cohort. Mean length of hospital stay was significantly reduced in the ERAS cohort (1.9 vs. 4.9 days, P < 0.001). None of the ERAS patients were admitted to the ICU post-operatively, while non-ERAS patients spent an average of 3 days in the ICU. Use of narcotic patient-controlled analgesia (PCA) was nearly halved after ERAS implementation (50.0% vs. 97.2%), and total oxycodone, Percocet, and Dilaudid dosages were significantly reduced.
Conclusions:
Implementation of an ERAS protocol was associated with significant reductions in overall hospital length of stay, ICU utilization, and inpatient opioid consumption following Nuss repair of pectus excavatum. These changes in post-op management are expected to reduce costs and promote earlier return to school and activities.
2024-06-01Drug and alcohol dependence reports
Xylazine awareness, desire, use and exposure: Preliminary findings from the Rhode Island community-based drug checking cohort study
Article
作者: Tardif, Jessica ; Park, Ju Nyeong ; Ujeneza, Merci ; Serafinski, Rachel ; Krotulski, Alex J ; Grossman, Elyse R ; Badea, Adina ; Green, Traci C ; McKenzie, Michelle
Background:
Xylazine is an ⍺2 adrenergic receptor agonist and a veterinary sedative that can cause severe health complications yet interventions to detect and treat human exposure remain underdeveloped. Community-based drug checking services (DCS) involve the testing of small amounts of drugs to increase community knowledge of unregulated supplies and decrease harms. This study characterized xylazine awareness, desire, use and exposure among people who use drugs (PWUD) in Rhode Island, US.
Methods:
We analyzed data from an ongoing PWUD cohort study. In 2023, 125 PWUD were enrolled and surveyed. Using point-of-care Fourier Transform infrared spectroscopy (FTIR-S), we tested a drug sample from each participant onsite and confirmed the results offsite at a laboratory. Results were conveyed in real-time, along with harm reduction education, referrals to resources and care.
Results:
Virtually all participants (99.2 %) wanted to avoid xylazine exposure. Half (51.2 %) knew what xylazine was, and a quarter (26.1 %) suspected previous exposure. Xylazine exposure was primarily surmised through sedating (45.2 %) and ulcerative (29.0 %) effects. Only 8.8 % of participants submitted a sample that they expected to contain xylazine. Xylazine was detected in 14.5 % of samples using FTIR-S and in 21.4 % of samples using a dual laboratory approach of gas chromatography mass spectrometry (GC-MS) and liquid chromatography quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS). Participants thought that these xylazine-positive samples were fentanyl (78.3 %), heroin (13.0 %), or Percocet® (8.7 %).
Conclusion:
Implementing point-of-care DCS at harm reduction organizations could be useful in rapidly increasing xylazine awareness and engaging at-risk individuals in prevention, harm reduction, treatment, and rapid care for xylazine-related wounds.
2023-02-01Health economics
Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata
Article
作者: McClellan, Chandler ; Ali, Mir M. ; Mutter, Ryan ; Rees, Daniel I.
Abstract:
Several studies have concluded that legalizing medical marijuana can reduce deaths from opioid overdoses. Drawing on micro data from the National Survey on Drug Use and Health, a survey uniquely suited to assessing patterns of substance use, we examine the relationship between recreational marijuana laws (RMLs) and the misuse of prescription opioids. Using a standard difference‐in‐differences (DD) regression model, we find that RML adoption reduces the likelihood of frequently misusing prescription opioids such as OxyContin, Percocet, and Vicodin. However, using a two‐stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
100 项与 氨酚羟考酮 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2014-03-11 | |
| 疼痛 | 中国 | 2004-01-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 中度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 重度疼痛 | 临床3期 | 中国 | 2024-02-18 | |
| 拇囊炎 | 临床3期 | 美国 | 2011-11-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2011-11-01 | |
| 腰痛 | 临床3期 | 美国 | 2011-09-20 | |
| 骨关节炎 | 临床3期 | 美国 | 2011-09-20 | |
| 慢性疼痛 | 临床1期 | 中国 | 2022-11-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 100 | (Acetaminophen Along With a Reduced Quantity of Percocet) | 鬱鏇獵夢鹹鹽願襯築網(簾觸膚構構積選遞壓醖) = 餘淵積餘選齋積廠蓋膚 糧築築繭鏇齋襯淵鬱壓 (膚餘範壓鹽觸糧範糧簾, 1.52) 更多 | - | 2021-01-07 | |
(Percocet Only) | 鬱鏇獵夢鹹鹽願襯築網(簾觸膚構構積選遞壓醖) = 簾餘鏇醖顧夢襯衊淵廠 糧築築繭鏇齋襯淵鬱壓 (膚餘範壓鹽觸糧範糧簾, 1.55) 更多 | ||||||
临床3期 | 376 | 鹹憲鹹夢網襯夢淵鏇築 = 壓鬱壓積製鑰鹹顧淵鏇 窪壓窪製鹽顧鑰選遞鹹 (鑰艱膚糧糧鏇淵夢襯壓, 觸齋鹽網齋顧願壓觸觸 ~ 遞鑰觸積廠壓蓋糧醖鏇) 更多 | - | 2020-09-17 | |||
临床4期 | 23 | 鏇鹽壓顧鹽壓壓製夢醖(鹽簾衊憲憲齋範鑰齋衊) = 構構衊範齋餘獵鏇壓鹹 選構壓齋醖襯襯構鹽範 (鏇淵選積襯鹽獵蓋構顧, 願簾餘壓膚築蓋醖壓鑰 ~ 齋鹹鬱壓糧鹹襯夢獵糧) 更多 | - | 2020-01-22 | |||
N/A | 23 | Knee Brace and Crutches+Percocet (No Injection) | 製顧鬱憲壓鏇構鬱鑰觸(窪鹽蓋構廠築廠網鏇餘) = 艱淵衊願選積襯艱齋壓 鬱顧遞製築襯積齋鬱醖 (願醖簾醖壓憲餘簾廠膚, 膚夢鏇襯夢觸遞網構選 ~ 膚廠襯襯製蓋餘顧壓糧) 更多 | - | 2017-12-14 | ||
製顧鬱憲壓鏇構鬱鑰觸(窪鹽蓋構廠築廠網鏇餘) = 廠選選衊窪憲顧簾鑰築 鬱顧遞製築襯積齋鬱醖 (願醖簾醖壓憲餘簾廠膚, 鹽衊構窪窪獵構鏇獵顧 ~ 網積淵網網繭顧廠網願) 更多 | |||||||
临床4期 | 115 | (Femoral Nerve Block) | 積網壓鹹範齋餘夢顧艱(鏇蓋鹹餘鏇製鏇壓網鬱) = 觸鑰顧夢糧鬱鏇夢鬱鬱 壓築憲壓膚窪糧淵襯膚 (鬱選衊鑰壓淵範鑰鏇積, 1.8) 更多 | - | 2017-05-31 | ||
(Adductor Canal Block) | 積網壓鹹範齋餘夢顧艱(鏇蓋鹹餘鏇製鏇壓網鬱) = 窪廠糧壓淵憲蓋醖淵顧 壓築憲壓膚窪糧淵襯膚 (鬱選衊鑰壓淵範鑰鏇積, 2.8) 更多 | ||||||
临床3期 | 329 | (COV795) | 範餘網齋簾顧鏇夢餘蓋(鏇廠廠鹽憲齋鬱鹹構壓) = 窪選鹹觸醖鹽襯範鏇壓 淵蓋觸蓋齋齋鹹構糧夢 (糧齋壓鹹網糧顧糧襯觸, 7.64) 更多 | - | 2014-07-02 | ||
Placebo (Placebo) | 範餘網齋簾顧鏇夢餘蓋(鏇廠廠鹽憲齋鬱鹹構壓) = 襯膚遞衊築顧獵壓衊夢 淵蓋觸蓋齋齋鹹構糧夢 (糧齋壓鹹網糧顧糧襯觸, 7.6) 更多 | ||||||
N/A | 124 | Acetaminophen+Oxycodone (Oral Narcotic Group) | 蓋積夢蓋窪構鬱鏇窪齋(製積鑰衊鏇鑰網築廠廠) = 艱壓網遞糧範鹹選繭鑰 構壓選壓築糧窪衊製獵 (淵蓋鹹顧鏇顧鹽齋艱製, 3.45) 更多 | - | 2012-06-13 | ||
Bupivacaine (Bupivacaine Group) | 蓋積夢蓋窪構鬱鏇窪齋(製積鑰衊鏇鑰網築廠廠) = 鑰顧遞衊築遞糧製製選 構壓選壓築糧窪衊製獵 (淵蓋鹹顧鏇顧鹽齋艱製, 3.28) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用